A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Mongersen (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 23 May 2017 Planned number of patients changed from 1414 to 1300.
    • 23 May 2017 Planned End Date changed from 1 Apr 2022 to 28 Oct 2022.
    • 23 May 2017 Planned primary completion date changed from 1 Mar 2022 to 30 Sep 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top